Skip to content

Biobank Leukemia, Myeloma, Lymfoma and Myelofibrosis

Biobank Leukemia, Myeloma, Lymfoma and Myelofibrosis - Biobank Hematology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47820
Enrollment
1950
Registered
2009-03-05
Start date
2009-04-29
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients 18 or older, able to state his/her wishes and has (or is suspected to have) a hematological disease.

Exclusion criteria

Exclusion criteria: If diagnosis demonstrates that the patient does not have any of the hematological diseases, as mentioned under the inclusion citeria, he/she is excluded.

Design outcomes

Primary

MeasureTime frame
This project intends to gain knowledge on the properties (such as DNA features) of the stored tissue or cells. These data are combined with clinical data of the disease, sensitivity to treatment and possibly with important environmental factors and patient data (i.e. age, previous diseases). From these analyses knowledge can be gained about: - the nature and possibly the origin of the disease - reasons why the disease responds well or poorly to the applied treatment - the treatment outcome.

Secondary

MeasureTime frame
A 'minimal dataset' describing the collected clinical data/variables, has been drafted for every hematological disease in agreement with all eight UMC's (see attachment 1 'Minimal dataset' of the 'Reglement Parel Leukemie, Myeloom, Lymfoom en Myelofibrosis, which is added to the Protocol Biobank 'Leukemie, Myeloom, Lymfklierkanker').

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)